Federal Government Increases Focus on Price Transparency | Health Care Economics, Insurance, Payment | JAMA Forum Archive | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
JAMA Forum Archive, 2012-2019: Health policy commentary from leaders in the field
JAMA Forum

Federal Government Increases Focus on Price Transparency

The Trump administration continues its focus on making information about medical costs more available as a strategy to help patients become more price- and cost-conscious in their choice of hospitals, physicians, and prescription drugs. The administration’s current effort to increase price transparency for hospitals stems from the 2019 inpatient and long-term care hospital proposed payment final rule.

The rule, which went into effect in January of 2019, requires hospitals to post charges for all services and items for which they bill patients or their insurance companies, including all procedures, tests, drugs, and any other service charges that may be associated with the patient’s care. The information has to be made available in a machine-readable format (a format easily processed by computers) on a hospital’s website. Requiring the easy accessibility of charge information to patients is a dramatic change in the attitude of hospitals; as a 2017 article in the New York Times described, hospitals regarded the codes and master price list comprising their billing strategies as “trade secrets” to be used as part of their negotiations with private payers.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words